Skip to content
Logo text: ISPOR Improving healthcare decisions

Health Technology Assessment Central

The HTA Resource Center for Informing Healthcare Decisions

  • Home
  • What Is HTA?
  • HTA News and Events
  • Resource Library
  • Governance
  • Policy Interchange
  • Training and Development
« Back to ISPOR.org

News

Novartis first to benefit from NICE advice on ‘patient preference’

February 18, 2019

http://www.pmlive.com/pharma_news/novartis_first_to_benefit_from_nice_advice_on_patient_preference_1278304

Posted in: Uncategorized

Post navigation

← NICE collaborates with the Canadian Agency for Drugs and Technology in Health to offer parallel scientific advice
UHC Act: The role of Health Technology →

News

Growing Patient Involvement in Health Technology Assessment (HTA)
NICE launches online resource to help development and adoption of new health technologies
CADTH Celebrates Health Technology Assessment Leaders
Canada to create national drug agency to help cut cost of medicines
Bermuda Health Council Accepted Into RedETSA
Health Canada & HTA Body CADTH To Offer Parallel Scientific Advice
UHC Act: The role of Health Technology
NICE collaborates with the Canadian Agency for Drugs and Technology in Health to offer parallel scientific advice
International HTA Agencies Collaborate On How To Determine Value-Based Prices
Japan shares its universal health coverage knowledge with Egypt

Twitter

Tweets about #HTA

#HTA

evers_silviaSilvia Evers@evers_silvia·
44m

@ErikKoffijberg of the @UTwente providing us great insights in the value of information analysis #voi as a way to handle #uncertainty in #healtheconomics during his keynote at the meeting of the Dutch Association of #HTA @NVTAG_nl

Reply on Twitter 1143870789734862848Retweet on Twitter 1143870789734862848Like on Twitter 11438707897348628481Twitter 1143870789734862848
VHC_CAPHRI_UMVHC_CAPHRI_UM@VHC_CAPHRI_UM·
51m

Key note speaker @ManuelaJoore giving great insights into handling #uncertainty in #HealthPolicy #decisionmaking during the meeting of the Dutch Association of #HTA @CAPHRI_UM @MaastrichtU

Reply on Twitter 1143868937064652800Retweet on Twitter 11438689370646528001Like on Twitter 11438689370646528002Twitter 1143868937064652800
SHTAC_uni_sotonSHTAC unisouthampton@SHTAC_uni_soton·
2h

We've just started working a new STA for NICE, Ustekinumab for treating moderately to severely active ulcerative colitis https://t.co/lzGODrBSmr #HTA #UlcerativeColitis #IBD

Reply on Twitter 1143858099649961985Retweet on Twitter 1143858099649961985Like on Twitter 1143858099649961985Twitter 1143858099649961985
Load More...
Privacy Policy | Disclaimer
Copyright © 2019 ISPOR – The Professional Society for Health Economics and Outcomes Research